CN101687849B - 艾普拉唑溶剂化物的晶形 - Google Patents
艾普拉唑溶剂化物的晶形 Download PDFInfo
- Publication number
- CN101687849B CN101687849B CN2007800488456A CN200780048845A CN101687849B CN 101687849 B CN101687849 B CN 101687849B CN 2007800488456 A CN2007800488456 A CN 2007800488456A CN 200780048845 A CN200780048845 A CN 200780048845A CN 101687849 B CN101687849 B CN 101687849B
- Authority
- CN
- China
- Prior art keywords
- intensity
- crystalline form
- crystal
- racemic ilaprazole
- peak
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- HRRXCXABAPSOCP-UHFFFAOYSA-N ilaprazole Chemical compound COC1=CC=NC(CS(=O)C=2NC3=CC(=CC=C3N=2)N2C=CC=C2)=C1C HRRXCXABAPSOCP-UHFFFAOYSA-N 0.000 title claims abstract description 95
- 229950008491 ilaprazole Drugs 0.000 title claims abstract description 95
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 32
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 230000027119 gastric acid secretion Effects 0.000 claims abstract description 13
- 230000002401 inhibitory effect Effects 0.000 claims abstract description 13
- 239000003937 drug carrier Substances 0.000 claims abstract description 5
- 239000013078 crystal Substances 0.000 claims description 100
- 238000000634 powder X-ray diffraction Methods 0.000 claims description 21
- 238000001228 spectrum Methods 0.000 claims description 13
- 238000013265 extended release Methods 0.000 claims 1
- 238000000034 method Methods 0.000 abstract description 27
- 230000002496 gastric effect Effects 0.000 abstract description 11
- 239000002253 acid Substances 0.000 abstract description 9
- HYZJCKYKOHLVJF-UHFFFAOYSA-N 1H-benzimidazole Chemical compound C1=CC=C2NC=NC2=C1 HYZJCKYKOHLVJF-UHFFFAOYSA-N 0.000 abstract description 2
- 125000000475 sulfinyl group Chemical group [*:2]S([*:1])=O 0.000 abstract description 2
- -1 4-methoxy-3-methyl-2-pyridinyl Chemical group 0.000 abstract 1
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 81
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 50
- 239000012453 solvate Substances 0.000 description 49
- 238000007614 solvation Methods 0.000 description 34
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical class CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 33
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 25
- 239000007787 solid Substances 0.000 description 22
- 239000002904 solvent Substances 0.000 description 21
- 150000001875 compounds Chemical class 0.000 description 20
- 239000000203 mixture Substances 0.000 description 17
- 238000002360 preparation method Methods 0.000 description 15
- 239000000612 proton pump inhibitor Substances 0.000 description 15
- 229940126409 proton pump inhibitor Drugs 0.000 description 15
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 14
- 238000010521 absorption reaction Methods 0.000 description 13
- MWUXSHHQAYIFBG-UHFFFAOYSA-N Nitric oxide Chemical compound O=[N] MWUXSHHQAYIFBG-UHFFFAOYSA-N 0.000 description 12
- 208000021302 gastroesophageal reflux disease Diseases 0.000 description 11
- 238000012545 processing Methods 0.000 description 10
- 210000002784 stomach Anatomy 0.000 description 10
- 239000003814 drug Substances 0.000 description 9
- 238000002329 infrared spectrum Methods 0.000 description 9
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 description 9
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 9
- 230000008569 process Effects 0.000 description 9
- 238000005481 NMR spectroscopy Methods 0.000 description 8
- 238000012937 correction Methods 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 238000009472 formulation Methods 0.000 description 8
- 238000001237 Raman spectrum Methods 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 238000001938 differential scanning calorimetry curve Methods 0.000 description 7
- 229940000406 drug candidate Drugs 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 238000002411 thermogravimetry Methods 0.000 description 7
- 239000000463 material Substances 0.000 description 6
- 230000006340 racemization Effects 0.000 description 6
- 230000028327 secretion Effects 0.000 description 6
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 5
- 239000000706 filtrate Substances 0.000 description 5
- 239000012535 impurity Substances 0.000 description 5
- 230000000704 physical effect Effects 0.000 description 5
- 238000005160 1H NMR spectroscopy Methods 0.000 description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 4
- 208000025865 Ulcer Diseases 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 210000000936 intestine Anatomy 0.000 description 4
- IOLCXVTUBQKXJR-UHFFFAOYSA-M potassium bromide Chemical compound [K+].[Br-] IOLCXVTUBQKXJR-UHFFFAOYSA-M 0.000 description 4
- 230000000087 stabilizing effect Effects 0.000 description 4
- 231100000397 ulcer Toxicity 0.000 description 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 3
- 208000023514 Barrett esophagus Diseases 0.000 description 3
- 208000023665 Barrett oesophagus Diseases 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 239000004677 Nylon Substances 0.000 description 3
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000008186 active pharmaceutical agent Substances 0.000 description 3
- 125000004390 alkyl sulfonyl group Chemical group 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000011903 deuterated solvents Substances 0.000 description 3
- 235000005911 diet Nutrition 0.000 description 3
- 230000037213 diet Effects 0.000 description 3
- 238000004090 dissolution Methods 0.000 description 3
- 239000002552 dosage form Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 208000000718 duodenal ulcer Diseases 0.000 description 3
- 210000001198 duodenum Anatomy 0.000 description 3
- 239000012065 filter cake Substances 0.000 description 3
- 210000001035 gastrointestinal tract Anatomy 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 238000002386 leaching Methods 0.000 description 3
- 229920001778 nylon Polymers 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 229920006395 saturated elastomer Polymers 0.000 description 3
- 230000003595 spectral effect Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229910052717 sulfur Inorganic materials 0.000 description 3
- 125000004434 sulfur atom Chemical group 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 239000003826 tablet Substances 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 2
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JHUUPUMBZGWODW-UHFFFAOYSA-N 3,6-dihydro-1,2-dioxine Chemical compound C1OOCC=C1 JHUUPUMBZGWODW-UHFFFAOYSA-N 0.000 description 2
- 229910000809 Alumel Inorganic materials 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- 238000005033 Fourier transform infrared spectroscopy Methods 0.000 description 2
- 208000005577 Gastroenteritis Diseases 0.000 description 2
- 208000018522 Gastrointestinal disease Diseases 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 241000590002 Helicobacter pylori Species 0.000 description 2
- 241000124008 Mammalia Species 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- PXHVJJICTQNCMI-UHFFFAOYSA-N Nickel Chemical group [Ni] PXHVJJICTQNCMI-UHFFFAOYSA-N 0.000 description 2
- 102100021904 Potassium-transporting ATPase alpha chain 1 Human genes 0.000 description 2
- 108010083204 Proton Pumps Proteins 0.000 description 2
- 238000001069 Raman spectroscopy Methods 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 2
- 229930006000 Sucrose Natural products 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052782 aluminium Inorganic materials 0.000 description 2
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000001556 benzimidazoles Chemical class 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000002354 daily effect Effects 0.000 description 2
- 230000003111 delayed effect Effects 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 208000010643 digestive system disease Diseases 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 238000009509 drug development Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000005516 engineering process Methods 0.000 description 2
- 239000012530 fluid Substances 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 210000004051 gastric juice Anatomy 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 208000018685 gastrointestinal system disease Diseases 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229940014259 gelatin Drugs 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 229910052732 germanium Inorganic materials 0.000 description 2
- GNPVGFCGXDBREM-UHFFFAOYSA-N germanium atom Chemical compound [Ge] GNPVGFCGXDBREM-UHFFFAOYSA-N 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229940037467 helicobacter pylori Drugs 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- 230000002045 lasting effect Effects 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000007726 management method Methods 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 238000002844 melting Methods 0.000 description 2
- 230000008018 melting Effects 0.000 description 2
- 238000012856 packing Methods 0.000 description 2
- 229920001223 polyethylene glycol Polymers 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 238000001179 sorption measurement Methods 0.000 description 2
- 239000005720 sucrose Substances 0.000 description 2
- 208000011580 syndromic disease Diseases 0.000 description 2
- 238000001757 thermogravimetry curve Methods 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 235000019731 tricalcium phosphate Nutrition 0.000 description 2
- 238000003828 vacuum filtration Methods 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- SUBDBMMJDZJVOS-UHFFFAOYSA-N 5-methoxy-2-{[(4-methoxy-3,5-dimethylpyridin-2-yl)methyl]sulfinyl}-1H-benzimidazole Chemical compound N=1C2=CC(OC)=CC=C2NC=1S(=O)CC1=NC=C(C)C(OC)=C1C SUBDBMMJDZJVOS-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- 108091006112 ATPases Proteins 0.000 description 1
- 244000215068 Acacia senegal Species 0.000 description 1
- 102000057290 Adenosine Triphosphatases Human genes 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- WSVLPVUVIUVCRA-KPKNDVKVSA-N Alpha-lactose monohydrate Chemical compound O.O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O WSVLPVUVIUVCRA-KPKNDVKVSA-N 0.000 description 1
- 239000005995 Aluminium silicate Substances 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 229910002483 Cu Ka Inorganic materials 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 235000019739 Dicalciumphosphate Nutrition 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- 206010013952 Dysphonia Diseases 0.000 description 1
- 206010063655 Erosive oesophagitis Diseases 0.000 description 1
- 102100021022 Gastrin Human genes 0.000 description 1
- 108010052343 Gastrins Proteins 0.000 description 1
- 208000007882 Gastritis Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 239000004705 High-molecular-weight polyethylene Substances 0.000 description 1
- NTYJJOPFIAHURM-UHFFFAOYSA-N Histamine Chemical class NCCC1=CN=CN1 NTYJJOPFIAHURM-UHFFFAOYSA-N 0.000 description 1
- 208000010473 Hoarseness Diseases 0.000 description 1
- XUJNEKJLAYXESH-REOHCLBHSA-N L-Cysteine Chemical compound SC[C@H](N)C(O)=O XUJNEKJLAYXESH-REOHCLBHSA-N 0.000 description 1
- 240000003183 Manihot esculenta Species 0.000 description 1
- 235000016735 Manihot esculenta subsp esculenta Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010030216 Oesophagitis Diseases 0.000 description 1
- BPQQTUXANYXVAA-UHFFFAOYSA-N Orthosilicate Chemical compound [O-][Si]([O-])([O-])[O-] BPQQTUXANYXVAA-UHFFFAOYSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 239000004141 Sodium laurylsulphate Substances 0.000 description 1
- 235000002595 Solanum tuberosum Nutrition 0.000 description 1
- 244000061456 Solanum tuberosum Species 0.000 description 1
- 239000005864 Sulphur Substances 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 235000010419 agar Nutrition 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 235000012211 aluminium silicate Nutrition 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000001262 anti-secretory effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 238000005102 attenuated total reflection Methods 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- CJZGTCYPCWQAJB-UHFFFAOYSA-L calcium stearate Chemical compound [Ca+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O CJZGTCYPCWQAJB-UHFFFAOYSA-L 0.000 description 1
- 239000008116 calcium stearate Substances 0.000 description 1
- 235000013539 calcium stearate Nutrition 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 229940105329 carboxymethylcellulose Drugs 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- AOXOCDRNSPFDPE-UKEONUMOSA-N chembl413654 Chemical compound C([C@H](C(=O)NCC(=O)N[C@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@H](CCSC)C(=O)N[C@H](CC(O)=O)C(=O)N[C@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](C)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=1C2=CC=CC=C2NC=1)NC(=O)[C@H]1N(CCC1)C(=O)CNC(=O)[C@@H](N)CCC(O)=O)C1=CC=C(O)C=C1 AOXOCDRNSPFDPE-UKEONUMOSA-N 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 208000013116 chronic cough Diseases 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 239000002872 contrast media Substances 0.000 description 1
- 230000008878 coupling Effects 0.000 description 1
- 238000010168 coupling process Methods 0.000 description 1
- 238000005859 coupling reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 238000005564 crystal structure determination Methods 0.000 description 1
- 235000018417 cysteine Nutrition 0.000 description 1
- 150000001945 cysteines Chemical class 0.000 description 1
- 230000001120 cytoprotective effect Effects 0.000 description 1
- 238000010908 decantation Methods 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 239000007950 delayed release tablet Substances 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000004807 desolvation Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- NEFBYIFKOOEVPA-UHFFFAOYSA-K dicalcium phosphate Chemical compound [Ca+2].[Ca+2].[O-]P([O-])([O-])=O NEFBYIFKOOEVPA-UHFFFAOYSA-K 0.000 description 1
- 229910000390 dicalcium phosphate Inorganic materials 0.000 description 1
- 229940038472 dicalcium phosphate Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 239000002702 enteric coating Substances 0.000 description 1
- 238000009505 enteric coating Methods 0.000 description 1
- 208000006881 esophagitis Diseases 0.000 description 1
- 230000003203 everyday effect Effects 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 238000011049 filling Methods 0.000 description 1
- 235000013312 flour Nutrition 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 208000015419 gastrin-producing neuroendocrine tumor Diseases 0.000 description 1
- 201000000052 gastrinoma Diseases 0.000 description 1
- 230000007160 gastrointestinal dysfunction Effects 0.000 description 1
- 210000004907 gland Anatomy 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 229940075507 glyceryl monostearate Drugs 0.000 description 1
- 108010067216 glycyl-glycyl-glycine Proteins 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- JEGUKCSWCFPDGT-UHFFFAOYSA-N h2o hydrate Chemical compound O.O JEGUKCSWCFPDGT-UHFFFAOYSA-N 0.000 description 1
- 239000007902 hard capsule Substances 0.000 description 1
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 1
- 239000003485 histamine H2 receptor antagonist Substances 0.000 description 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 229910052738 indium Inorganic materials 0.000 description 1
- APFVFJFRJDLVQX-UHFFFAOYSA-N indium atom Chemical compound [In] APFVFJFRJDLVQX-UHFFFAOYSA-N 0.000 description 1
- 208000027866 inflammatory disease Diseases 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- NLYAJNPCOHFWQQ-UHFFFAOYSA-N kaolin Chemical compound O.O.O=[Al]O[Si](=O)O[Si](=O)O[Al]=O NLYAJNPCOHFWQQ-UHFFFAOYSA-N 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000011866 long-term treatment Methods 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 235000012254 magnesium hydroxide Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037323 metabolic rate Effects 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 239000001788 mono and diglycerides of fatty acids Substances 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229910052759 nickel Inorganic materials 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000001208 nuclear magnetic resonance pulse sequence Methods 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 229960000381 omeprazole Drugs 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940100691 oral capsule Drugs 0.000 description 1
- 229940096978 oral tablet Drugs 0.000 description 1
- 239000007935 oral tablet Substances 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 239000002831 pharmacologic agent Substances 0.000 description 1
- 229940023488 pill Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 210000002381 plasma Anatomy 0.000 description 1
- 206010036067 polydipsia Diseases 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000004224 protection Effects 0.000 description 1
- 238000010298 pulverizing process Methods 0.000 description 1
- 238000010926 purge Methods 0.000 description 1
- 150000003856 quaternary ammonium compounds Chemical class 0.000 description 1
- 150000003254 radicals Chemical class 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 238000002310 reflectometry Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000452 restraining effect Effects 0.000 description 1
- 150000003839 salts Chemical group 0.000 description 1
- 210000002955 secretory cell Anatomy 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 238000004467 single crystal X-ray diffraction Methods 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000007909 solid dosage form Substances 0.000 description 1
- 238000002336 sorption--desorption measurement Methods 0.000 description 1
- 239000007921 spray Substances 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 238000000967 suction filtration Methods 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000031068 symbiosis, encompassing mutualism through parasitism Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009897 systematic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 238000010257 thawing Methods 0.000 description 1
- 229940078499 tricalcium phosphate Drugs 0.000 description 1
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 1
- GZXOHHPYODFEGO-UHFFFAOYSA-N triglycine sulfate Chemical compound NCC(O)=O.NCC(O)=O.NCC(O)=O.OS(O)(=O)=O GZXOHHPYODFEGO-UHFFFAOYSA-N 0.000 description 1
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 description 1
- 229940038773 trisodium citrate Drugs 0.000 description 1
- 210000002438 upper gastrointestinal tract Anatomy 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 210000001215 vagina Anatomy 0.000 description 1
- 230000004304 visual acuity Effects 0.000 description 1
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US87760806P | 2006-12-29 | 2006-12-29 | |
| US60/877,608 | 2006-12-29 | ||
| US88749907P | 2007-01-31 | 2007-01-31 | |
| US60/887,499 | 2007-01-31 | ||
| PCT/US2007/089137 WO2008083341A1 (en) | 2006-12-29 | 2007-12-28 | Crystalline forms of solvated ilaprazole |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101687849A CN101687849A (zh) | 2010-03-31 |
| CN101687849B true CN101687849B (zh) | 2013-05-29 |
Family
ID=39313094
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800488456A Expired - Fee Related CN101687849B (zh) | 2006-12-29 | 2007-12-28 | 艾普拉唑溶剂化物的晶形 |
| CN2007800488403A Active CN101687848B (zh) | 2006-12-29 | 2007-12-28 | 外消旋艾普拉唑的固体形式 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2007800488403A Active CN101687848B (zh) | 2006-12-29 | 2007-12-28 | 外消旋艾普拉唑的固体形式 |
Country Status (18)
| Country | Link |
|---|---|
| US (4) | US7999110B2 (enExample) |
| EP (2) | EP2102192B1 (enExample) |
| JP (2) | JP5315253B2 (enExample) |
| KR (3) | KR20110091594A (enExample) |
| CN (2) | CN101687849B (enExample) |
| AU (2) | AU2007341984B2 (enExample) |
| CA (2) | CA2674358C (enExample) |
| DK (1) | DK2102192T3 (enExample) |
| ES (1) | ES2398846T3 (enExample) |
| IL (2) | IL199242A (enExample) |
| MX (2) | MX2009006529A (enExample) |
| MY (2) | MY145936A (enExample) |
| NO (2) | NO20092398L (enExample) |
| NZ (2) | NZ577509A (enExample) |
| PL (1) | PL2102192T3 (enExample) |
| PT (1) | PT2102192E (enExample) |
| RU (2) | RU2464270C2 (enExample) |
| WO (2) | WO2008083341A1 (enExample) |
Families Citing this family (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101144600B1 (ko) * | 2009-12-08 | 2012-05-16 | 일양약품주식회사 | 일라프라졸의 결정형 ａ, ｂ의 제조방법 및 이들 결정형의 변환방법 |
| CN103204843B (zh) * | 2012-01-13 | 2014-12-31 | 丽珠医药集团股份有限公司 | 结晶型艾普拉唑钠乙醇化物及其制备方法 |
| CN103204842B (zh) * | 2012-01-13 | 2014-10-15 | 丽珠医药集团股份有限公司 | 结晶型艾普拉唑钠水合物及其制备方法 |
| WO2013114232A1 (en) * | 2012-02-02 | 2013-08-08 | Lupin Limited | Process for preparation of crystalline form l of ilaprazole |
| CN102746275B (zh) * | 2012-06-21 | 2014-07-16 | 丽珠医药集团股份有限公司 | 结晶型艾普拉唑钠及其制备方法 |
| CN102746277B (zh) * | 2012-06-21 | 2014-05-14 | 丽珠医药集团股份有限公司 | 一种结晶形式的艾普拉唑钠及其制备方法 |
| CN103172618B (zh) * | 2013-02-27 | 2014-09-03 | 丽珠医药集团股份有限公司 | 艾普拉唑晶型及其制备方法 |
| CN104370886B (zh) * | 2014-11-18 | 2016-05-18 | 宁夏康亚药业有限公司 | 艾普拉唑晶型及其制备方法和应用 |
| CN105055342A (zh) * | 2015-08-13 | 2015-11-18 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗消化性溃疡的药物艾普拉唑钠组合物冻干粉针剂 |
| CN105055343A (zh) * | 2015-08-31 | 2015-11-18 | 青岛蓝盛洋医药生物科技有限责任公司 | 一种治疗胃病的药物艾普拉唑钠组合物冻干粉针剂 |
| CN106749191A (zh) * | 2016-12-10 | 2017-05-31 | 珠海保税区丽珠合成制药有限公司 | 艾普拉唑晶型ⅱ及其制备方法 |
| KR101961028B1 (ko) * | 2017-10-12 | 2019-03-21 | 중앙대학교 산학협력단 | 일라프라졸을 유효성분으로 함유하는 급성 위염의 예방 또는 치료용 약학 조성물 |
| KR102332996B1 (ko) * | 2020-04-13 | 2021-12-01 | 중앙대학교 산학협력단 | 일라프라졸을 유효성분으로 함유하는 장폐색증 예방 또는 치료용 약학조성물 |
| KR20220065235A (ko) | 2020-11-13 | 2022-05-20 | 주식회사 파마코스텍 | 일라프라졸 혼형 결정의 신규한 제조방법 |
| KR102250509B1 (ko) | 2020-12-09 | 2021-05-11 | 유니셀랩 주식회사 | 새로운 일라프라졸/자일리톨 공결정 |
| KR20210019469A (ko) | 2021-02-02 | 2021-02-22 | 주식회사 파마코스텍 | 일라프라졸 나트륨 결정형 및 신규한 제조방법 |
| CN117050060A (zh) * | 2023-07-20 | 2023-11-14 | 浙江美诺华药物化学有限公司 | 一种艾普拉唑晶型f的制备方法 |
| KR20250156870A (ko) | 2024-04-25 | 2025-11-04 | 엠에프씨 주식회사 | 일라프라졸 마그네슘염 수화물의 제조방법 |
| CN119462610A (zh) * | 2024-11-06 | 2025-02-18 | 甘肃皓天科技股份有限公司 | 一种艾普拉唑新晶型及其制备方法 |
Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1121714A (zh) * | 1994-02-28 | 1996-05-01 | 一洋药品株式会社 | 新的5-吡咯基-2-吡啶基甲基亚磺酰基苯并咪唑衍生物 |
| WO2006118534A1 (en) * | 2005-05-04 | 2006-11-09 | Astrazeneca Ab | Proton pump inhibitors in the treatment of sleep disturbance due to silent gastro-esophageal reflux |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6331539B1 (en) | 1999-06-10 | 2001-12-18 | 3M Innovative Properties Company | Sulfonamide and sulfamide substituted imidazoquinolines |
| RU2232159C2 (ru) * | 1999-07-29 | 2004-07-10 | Регентский Совет Университета Калифорнии | Производные бензимидазола и фармацевтические композиции, содержащие пролекарство ингибитора протонного насоса |
| US6627646B2 (en) * | 2001-07-17 | 2003-09-30 | Sepracor Inc. | Norastemizole polymorphs |
| AU2003224779A1 (en) | 2002-03-27 | 2003-10-13 | Teva Pharmaceutical Industries Ltd. | Lansoprazole polymorphs and processes for preparation thereof |
| ES2375298T3 (es) | 2005-03-25 | 2012-02-28 | Livzon Pharmaceutical Group Inc. | Procedimiento para preparar derivados de sulfóxido sustituidos. |
-
2007
- 2007-12-28 US US11/966,868 patent/US7999110B2/en active Active
- 2007-12-28 KR KR1020117016139A patent/KR20110091594A/ko not_active Withdrawn
- 2007-12-28 KR KR1020097013519A patent/KR101052387B1/ko active Active
- 2007-12-28 MX MX2009006529A patent/MX2009006529A/es active IP Right Grant
- 2007-12-28 MX MX2009006530A patent/MX2009006530A/es active IP Right Grant
- 2007-12-28 CN CN2007800488456A patent/CN101687849B/zh not_active Expired - Fee Related
- 2007-12-28 WO PCT/US2007/089137 patent/WO2008083341A1/en not_active Ceased
- 2007-12-28 CN CN2007800488403A patent/CN101687848B/zh active Active
- 2007-12-28 NZ NZ577509A patent/NZ577509A/en not_active IP Right Cessation
- 2007-12-28 JP JP2009544309A patent/JP5315253B2/ja active Active
- 2007-12-28 MY MYPI20092734A patent/MY145936A/en unknown
- 2007-12-28 KR KR1020097013491A patent/KR20090086121A/ko not_active Ceased
- 2007-12-28 EP EP07870091A patent/EP2102192B1/en active Active
- 2007-12-28 JP JP2009544310A patent/JP5315254B2/ja not_active Expired - Fee Related
- 2007-12-28 CA CA2674358A patent/CA2674358C/en not_active Expired - Fee Related
- 2007-12-28 ES ES07870091T patent/ES2398846T3/es active Active
- 2007-12-28 EP EP07866107A patent/EP2102191B1/en active Active
- 2007-12-28 DK DK07870091.1T patent/DK2102192T3/da active
- 2007-12-28 NZ NZ577129A patent/NZ577129A/en unknown
- 2007-12-28 WO PCT/US2007/089127 patent/WO2008083333A1/en not_active Ceased
- 2007-12-28 RU RU2009122242/04A patent/RU2464270C2/ru not_active IP Right Cessation
- 2007-12-28 PL PL07870091T patent/PL2102192T3/pl unknown
- 2007-12-28 MY MYPI20092733A patent/MY146462A/en unknown
- 2007-12-28 CA CA2674347A patent/CA2674347C/en active Active
- 2007-12-28 AU AU2007341984A patent/AU2007341984B2/en active Active
- 2007-12-28 PT PT78700911T patent/PT2102192E/pt unknown
- 2007-12-28 RU RU2009122241/04A patent/RU2466129C2/ru active
- 2007-12-28 US US11/966,896 patent/US7989632B2/en not_active Expired - Fee Related
- 2007-12-28 AU AU2007341992A patent/AU2007341992B2/en not_active Ceased
-
2009
- 2009-06-08 IL IL199242A patent/IL199242A/en not_active IP Right Cessation
- 2009-06-08 IL IL199234A patent/IL199234A/en active IP Right Grant
- 2009-06-24 NO NO20092398A patent/NO20092398L/no not_active Application Discontinuation
- 2009-06-29 NO NO20092464A patent/NO342530B1/no unknown
-
2010
- 2010-11-04 US US12/939,266 patent/US8592599B2/en not_active Expired - Fee Related
- 2010-11-04 US US12/939,276 patent/US8592600B2/en not_active Expired - Fee Related
Patent Citations (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1121714A (zh) * | 1994-02-28 | 1996-05-01 | 一洋药品株式会社 | 新的5-吡咯基-2-吡啶基甲基亚磺酰基苯并咪唑衍生物 |
| WO2006118534A1 (en) * | 2005-05-04 | 2006-11-09 | Astrazeneca Ab | Proton pump inhibitors in the treatment of sleep disturbance due to silent gastro-esophageal reflux |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN101687849B (zh) | 艾普拉唑溶剂化物的晶形 | |
| US9108961B2 (en) | Crystalline form of (R)-7-chloro-N-(quinuclidin-3-yl)benzo[b]thiophene-2-carboxamide hydrochloride | |
| NO339021B1 (no) | (S)-(-)-1-(4-fluorisokinolin-5-yl)-sulfonyl-2-metyl-1,4-homopiperazinhydrokloriddihydrat samt fremgangsmåte for fremstilling av samme | |
| HK1225719A1 (en) | Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl) benzo(b)thiophene-2-carboxamide hydrochloride monohydrate | |
| US20200030306A1 (en) | 1-[(pyridin-3-yl-sulfonyl)-1h-pyrrol-3-yl] methanamine derivative and pharmaceutical composition and use thereof | |
| US20220298117A1 (en) | Crystalline forms of [3-(4- {2-butyl-1-[4-(4-chloro-phenoxy)-phenyl]-1h-imidazol-4-yl} -phenoxy)-propyl]-diethyl-amine | |
| AU2012257360A1 (en) | Polymorph of Rifaximin and process for the preparation thereof | |
| MX2007012605A (es) | Formas cristalinas novedosas de armodafinil y preparacion de ellas. | |
| JP2024542840A (ja) | Ｆｇｆｒ阻害剤の固体状形態 | |
| US8772488B2 (en) | Crystals of prasugrel hydrobromate | |
| US20230339918A1 (en) | Crystal forms of crenolanib and methods of use thereof | |
| TWI664172B (zh) | 來那度胺的晶型及其製備方法和用途 | |
| CN118401510A (zh) | 1-磺酰基吡咯衍生物的新颖盐类、其制备方法及包含其的药物组合物 | |
| RU2376304C2 (ru) | Моногидрат натриевой соли s-тенатопразола и его применение в качестве ингибитора протонного насоса | |
| CN109422741A (zh) | 化合物的盐及其晶型 | |
| TWI905226B (zh) | 克萊拉尼的晶型及其使用方法 | |
| US20250197393A1 (en) | Integrin inhibitor and uses thereof | |
| CN112513026A (zh) | Lta4h抑制剂的晶型 | |
| WO2024027695A1 (zh) | 作为her2抑制剂的化合物 | |
| HK1140483B (en) | Crystalline forms of solvated ilaprazole | |
| CN121079430A (zh) | 唾液酸衍生物的结晶形式及其使用方法 | |
| WO2025059801A1 (zh) | 一种嘧啶苯胺类化合物的晶型、制备方法及应用 | |
| CN113956245A (zh) | 克莱拉尼的晶型及其使用方法 | |
| TW202515572A (zh) | 一種嘧啶苯胺類化合物的晶型、製備方法及應用 | |
| CN116354956A (zh) | 维利西呱晶型及其制备方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: DE Ref document number: 1140483 Country of ref document: HK |
|
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| REG | Reference to a national code |
Ref country code: HK Ref legal event code: GR Ref document number: 1140483 Country of ref document: HK |
|
| C17 | Cessation of patent right | ||
| CF01 | Termination of patent right due to non-payment of annual fee |
Granted publication date: 20130529 Termination date: 20131228 |